Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417766 · ClinicalTrials.gov registry record
NIAID Clinical Center Genomics Opportunity Protocol
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 139
- Enrollment target
NCT02417766: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02417766 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02417766 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
Background: \- There are many types of immune disorders. These range from rare immune deficiencies to allergies to autoimmune disease like rheumatoid arthritis. Genes are the instructions our body uses to work and develop. A new technology called whole exome sequencing may help find the cause of these disorders. Whole exome sequencing is a way to look at many genes at once for errors. Researchers hope to find new gene changes that lead to immune disorders. Additionally, researchers are interested in finding the best way to manage unexpected but important findings by whole exome sequencing. Objectives: \- To better understand genetic causes of immune system disorders. Also, to better understand people s thoughts and feelings about immune system disorders and new genomic testing. Eligibility: \- People ages 0 100 with an immune disorder or a relative with an immune disorder. People must be at least 2 to be evaluated at the NIH clinical center. People must be at least 12 to do the survey/interview portion of the study. Design: * Participants will have their genes sequenced. They may be asked for a new sample of blood. * If participants cannot come for a study visit, they can have a blood sample collected by their local lab or doctor and sent by mail. * Researchers may or may not find the cause of the participant s immune disorder. Participants will learn that information. Some participants may be asked to return to NIH to get results and have more tests. * Researchers may share information with other studies. The data will be anonymous. * For the survey part of the study, participants will answer questions about their or their relative s immune disorder. They will also answer about their thoughts and feelings about genomic testing. * Some participants will be asked for a brief interview to ask more about the survey topics. There may be more follow-up after several months.
Primary Outcome
determination of discrete genotypephenotype association for selected immune-mediated disorders
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2015-06-29 |
| Est. Completion | 2019-01-22 |
What the finished NCT02417766 record still lists
NCT02417766 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02417766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02417766 about?
NCT02417766 is a clinical study titled "NIAID Clinical Center Genomics Opportunity Protocol". Background: \- There are many types of immune disorders. These range from rare immune deficiencies to allergies to autoimmune disease like rheumatoid arthritis. Genes are the instructions our body uses to work and develop. A new technology called whole exome sequencing may help find the cause of th...
What is the current status of trial NCT02417766?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2015-06-29. Estimated completion is 2019-01-22.
Who is sponsoring clinical trial NCT02417766?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI